Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 836 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Control Clear all
Completed Phase 1Phase 2 Interventional Results available

CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)

NCT04760613
View directory record Official record
Conditions
Radiculopathy
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT04786340
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

BMS-741672 for Diabetic Neuropathic Pain

NCT00683423
View directory record Official record
Conditions
Neuropathic Pain
Interventions
BMS-741672, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Tustin, California • Palm Beach Gardens, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

NCT02068027
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions
Clonidine Gel 0.1%, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
23
States / cities
Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

NCT05740813
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020
View directory record Official record
Conditions
Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions
MTR-601
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT00375960
View directory record Official record
Conditions
Pain, Diabetic Neuropathies
Interventions
V3381, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Walnut Creek, California • Clearwater, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2007 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

NCT01128855
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
3 mg/kg GSK2402968, 6 mg/kg GSK2402968, 9 mg/kg GSK2402968, 12 mg/kg GSK2402968, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jun 11, 2026, 5:26 AM EDT
Active, not recruiting Not applicable Interventional

Inspiratory Muscle Training Immediately After Lung Transplantation

NCT05309551
View directory record Official record
Conditions
Lung Transplantation, Chronic Lung Disease, Muscle Weakness, Rehabilitation
Interventions
IMT- Intervention group, IMT- Placebo group
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT00041795
View directory record Official record
Conditions
Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy
Interventions
leteprinim potassium (Neotrofin)
Drug
Lead sponsor
NeoTherapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Berkeley, California • Burbank, California • Mission Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Early Phase 1 Interventional

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

NCT00802815
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Etanercept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jun 11, 2026, 5:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
27
States / cities
Homewood, Alabama • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 11, 2026, 5:26 AM EDT
Recruiting Phase 3 Interventional

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

NCT06799247
View directory record Official record
Conditions
Myasthaenia Gravis
Interventions
Decartes-08, Placebo Drug
Biological · Other
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Tucson, Arizona • Carlsbad, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy

NCT02971072
View directory record Official record
Conditions
Acute Pain, Atrophic, Goals, Impairment, Infiltration, Injury, Muscle Weakness, Pain, Pathology, Shoulder Pain, Syndrome, Tendinopathy
Interventions
Subacromial injection, Physical Therapy
Procedure · Other
Lead sponsor
University of Oregon
Other
Eligibility
21 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nociceptive Pain Fiber Response

NCT02696070
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

NCT02017912
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Nurown MSC-NTF cells, Placebo
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

NCT02297412
View directory record Official record
Conditions
Acute Pain, Breast Carcinoma, Peripheral Neuropathy
Interventions
Minocycline Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Not applicable Interventional

RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS

NCT05273372
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Fatigue
Interventions
Placebo, Medical Food - Anhydrous Enol-Oxaloacetate
Other
Lead sponsor
Terra Biological LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Terminated Not applicable Interventional

Micro-Electrodes Implanted in a Human Nerve

NCT02034461
View directory record Official record
Conditions
Amputations, Peripheral Nerve Injury, Spinal Cord Injury
Interventions
Utah Slanted Electrode Array
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 3 Interventional

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

NCT00612170
View directory record Official record
Conditions
Fibromyalgia
Interventions
[S,S]-Reboxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
136
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RIIP REPS Neuromuscular Training

NCT07221305
View directory record Official record
Conditions
Neuromuscular Control, Healthy, Athletic Performance and Injury Risk
Interventions
Neuromuscular Control Training
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 18 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

NCT01625182
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Fingolimod, Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Orange, California • Miami, Florida • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jun 11, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jun 11, 2026, 5:26 AM EDT